Amgen to Take $2.7 Billion Stake in BeiGene for China Growth
Amgen Inc.’s rheumatoid arthritis treatment Enbrel is arranged at Skenderian Apothecary in Cambridge, Massachusetts. (Photographer: JB Reed/Bloomberg News)

Amgen to Take $2.7 Billion Stake in BeiGene for China Growth

(Bloomberg) -- Amgen Inc. will take a 20.5% stake in Chinese-American drug developer BeiGene Ltd. under a deal to develop and commercialize about two dozen of Amgen’s on-market and experimental can...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.